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Review Articles
Esophageal Cancer - a review
A. Alidina, T. Siddiqui, I. Burney, W. Jafri, F. Hussain, M. Ahmed*
Departments of Medicine and Surgery*, The Aga Khan University, Karachi.

Introduction
Esophageal cancer is a highly virulent malignancy,
where the overall cure rate is <10%. At presentation,
systemic disease is found in over 50% of the cases, leading
to incurability. Of the patients that present with locoregional disease, most will relapse with the primary therapy,
leaving the cure rate in this group to 12-35%.1-3 The most
commonly accepted standard of care for localized disease is
surgical resection. Neoadjuvant chemoradiotherapy given
as a combined modality therapy leads to pathological
responses to 20-40%, which could be the surrogate markers
to cure. Newer agents and targeted therapies will have an
important role in the care of esophageal cancer.
Epidemiology
World wide, esophageal cancer is the fourth most
common malignancy, after gastric, colorectal and
hepatocelluar malignancies. It is the 10th most common
malignancy (3.9%), but is the 6th leading cause of cancer
death (5.9%). World over, 316,000 new cases are diagnosed
each year, of which 286,000 die. In the USA, the cure rate
does not appear to be any better. Each year 13,000 new
cases are diagnosed, of which 12,600 will die.1-3 Data from
Karachi showed that it is the 7th most common malignancy
in men and 6th most common malignancy in females.4 At
AKUH, this was the 10th most common in men (5%)5 ,
while at Cenar, Quetta, this was the 3rd most common
malignancy in men, accounting for 11% of all cancers seen.6
This uneven distribution is at least partly because Cenar has
radiation therapy, where referrals would be higher. This may
also suggest that perhaps there are higher cases of
esophageal cancer in that part of Pakistan as compared to
Karachi, owing to the meeting of the border of Baluchistan
with Iran and Afghanistan, parts of where this disease is
endemic. However definitive epidemiological data is
lacking. While in the West, adenocarcinoma is the most
prevalent histology, world over, including Pakistan;
squamous cell carcinoma is the predominant histology.1,2,7
The incidence is as high as 100/100,000 cases in some parts
of the world, including parts of Iran, China and USSR.
South East Asia has intermediate probability of about 1050/100,000, and the West, including the USA has low
incidence of about <10/100,000.1,2
The median age at presentation in our country is 55
years. Male: female ratio is 1.2:1. Lower esophageal
cancers account for 44-60% of cases, mid esophagus 3054% and upper esophagus 10-25%.
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Risk Factors
Tobacco use is strongly associated with esophageal
cancer. In one study, 78% of all cases were tobacco users.
Niswar and betel nut use is also implicated as a risk factor.
It is known that smoking increases the risk of developing
squamous cell carcinoma of the esophagus by 5-10 folds,
and of developing adenocarcinoma by 2 fold. Molecular
changes, including p53 mutation with smoking heralds the
development of malignancy. Alcohol has additive and
perhaps synergistic effect, where the risk increases to as
high as 100 folds. 8-11 The raise in the adenocarcinoma of the
esophagus in the West may be attributable to the raise in the
prevalence of Barrett's Esophagus, a well-recognized risk
factor. This may be related to Helicobacter Pylori infection,
the incidence of which is decreasing, leading to less
atrophic gastritis and higher gastroesophageal reflux
disease. 12,13 About 1-3% of these patients with Barrett's
Esophagus will develop adenocarcinoma, 3% will develop
high grade dysplasia, and 15% low grade dysplasia. 14,15
Determining flow cytometric and molecular studies in
patients with Barrett's and dysplasia appear useful to
indicate which patients will develop invasive
malignancy. 16,17 However, this needs more studies before
becoming a standard part of surveillance endoscopy. The
American Society of Gastroenterology guidelines for
surveillance endoscopy in patients with Barrett's Esophagus
calls for endoscopic evaluation every 3-5 years in patients
with no dysplasia and every 6-12 months in patients with
low grade dysplasia. For patients with high-grade dysplasia,
options include intensive surveillance done every 3 months,
ablative therapy or esophagectomy. 18
Molecular Analysis
The unfavorable biology of patients with esophageal
cancers explains at least partly why these patients do poorly.
Targeted therapies against these molecular anomalies show
promise in the future of this malignancy. Like any other
malignancy, over expression of protooncogenes and
suppression of tumor suppressor genes will lead to
esophageal cancer. Recognized oncogenes include
Epidermal Growth Factor Receptors, Cyclin D1 and
Telomerase. Tumor suppressor genes implicated in this
malignancy include Rb gene, p53, p16, and 3p (FHIT). The
cell cycle progression requires that the growth factors be
activated, resulting in the expression and binding of Cyclins
and Cyclin Dependent Kinases (CDK). This leads the cell to
move from G1 to S to G2 and then to M phase where the
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Table 1. Early disease: treatment results - adjuvant setting.
Group of

Treatment arms

Radiotherapy

Chemotherapy

institution

No. of

Japanese Esophageal

Operation+cisplatin and

Oncology Group 43

vindesine/operation +

50 Gy

Cisplatin

258

vindesine

Japanese Esophageal
Group 44

Operation + adjuvant

No significant difference in
survival up to 5 years in the

radiotherapy

Oncology

Results

patients

2 groups (44% vs. 42%)
None

Cisplatin

205

chemotherapy

Adjuvant chemotherapy using
cisplatin and vindesine has
no additive effect on survival
in patients with esophageal
cancer compared to surgery
alone

Japan Clinical Oncology

Operation + adjuvant

Group 45

chemotherapy

None

Cisplatin

205

vindesine

The 5-year survival was 44.9%
in the surgery alone group
and 48.1% in the surgery
plus chemotherapy group

French University

Operation +

45 to 55 Gy

None

221

Association for
Surgical

Postoperative radiation therapy
did not improve survival. The

Research 46

recurrence rate was lower in
patients receiving radiation
therapy as compared with those
with surgery alone

University of Hong Kong,
Queen Mary

Hospital 47

Operation +

49 Gy after

None

130

The overall median survival

radiotherapy

curative resection

of patients after postoperative

and 52.5 Grays

radiotherapy was 8.7 months,
which was shorter than the
15.2 months for the control
groups (p = 0.02).

cell finally divides. Cyclin D-CDK 4/6 complexes result in
the phosphorylation of RB gene product that then cannot
bind to and inhibit the Transcription factors. The cycle
moves on to the S phase where more Cyclin/CDK
complexes cause the cells to go forward.19,20
Tumor suppressor gene p53 product regulates cellcycle progression, DNA repair, apoptosis and
neovascularization. It also inhibits the vascular endothelial
growth factor. Approximately 50-80% of esophageal
cancers express p53 mutation; here it correlates with
disease-free and overall survival. P53 mutation is also an
early event in the development of dysplasia.21-24 Epidermal
Growth Factor Receptor is a 170-kD tyrosine kinase
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receptor, activation of which results in overexpression of
Cyclins and CDKs. Overexpression is more commonly seen
in squamous cell carcinoma and confers unfavorable
prognosis.25-27 Overexpression of Cyclin D1 protooncogene
is seen in 40-60% of esophageal cancer and is more
commonly associated with advanced stage, leading to
diminish overall survival. Mutations in Rb and p16 genes
are seen in 20-60% of esophageal cancer and again, results
in poor prognosis.28-32 Telomerase synthesizes telomeres,
which are DNA sequences found at the ends of
chromosomes, that then protects the chromosomes from
recombination, nuclease attacks, activation of cell-cycle
check point, and end-to-end fusion. All these functions of
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Table 2. Early disease: treatment results - neoadjuvant setting.
Group or
institution

Treatment arms

Radiotherapy

Regional Cancer
Institute, Centre
Eugene Marquis48

Operation +
preoperative
chemotherapy

20 Gy

5-FU
Cisplatin

86

Long term survival was not
significantly different, with 47%
of both groups with squamous cell
carcinoma of the esophagus
alive at 1 year

University of
Michigan Medical
Center4 9

Operation +
preoperative
chemoradiation

45 Gy

Cisplatin
5-FU
vinblastine

100

The two groups did not demonstrate
a statistically significant survival
difference

University Hospital
J. Minjoz,
Besancon, France50

Operation +
preoperative
chemoradiation

18.5 Gy

Cisplatin

297

Preoperative chemoradiotherapy
did not improve overall survival,
but it did prolong disease-free
survival and survival free of
local disease. The median
survival was 18.6 months for
both groups.

St. James’s
Hospital, Dublin,
Ireland51

Operation +
preoperative

40 Gy

Fluorouracil
cisplatin

102

The median survival of patients
assigned to multimodal therapy
was 16 months, as compared with
11 months for those assigned to
surgery alone (p = 0.01)

Memorial SloanKettering Cancer,
New York 53

Operation +
preoperative

None

Fluorouracil
cisplatin

440

After 55.4 months, there were no
significant differences between
the two groups in median survival:
14.9 months for the preoperative
chemotherapy and 16.1 months
for the surgery only group
(p = 0.53)

UK Medial
Research Council
Upper GI Tract
Cancer Group54

Operation +
preoperative
chemotherapy

Fluorouracil
cisplatin

802

In patients with resectable esophageal
cancer, two cycles of pre-operative
cisplatin and fluorouracil improved
survival without incurring additional
serious adverse events. Median
survival was 17.2 months compared
with 13.3 months (difference 3.9
months; 95% CI 1.1-6.9 months)

Radiation
Therapy
Oncology Group55

Combined
chemoradiotherapy and

50 Gy

Chemotherapy

Fluorouracil
cisplatin

telomeres will protect the malignant cells from breakdown.
Overexpression of telomerase is seen in many malignancies
including esophageal cancer. 33-36
Staging and Survival
In one local study, virtually all patients presented with
stages III and IV. Dysphagia and loss of weight are found
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No. of
patients

Results

Combined therapy increases the
survival of patients who have
squamous cell or adenocarcinoma
of the esophagus, T1-3 NO-1 MO,
compared with RT alone

in 93% and 75% of cases respectively. Other symptoms
include anorexia, chest pains and GI bleed. Median
duration of symptoms is 3-4 months.
The anatomical location accounts for two
unfavorable features resulting in poor survival. Firstly,
esophagus has an indistinct serosa. Secondly, this organ has
a unique lymphatic anatomy. Much unlike the other GI
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Table 3. Metastatic disease - treatment results.
Group or
institution

Treatment arms

Radiotherapy

Chemotherapy No. of
patients

Results

Institut J.
Bordet, Brussels,
Belgium57

Cisplatin + 5-FU

None

Cisplatin +
5-FU

88

The response rate was 35% and 19% and the
median duration of survival was 33 weeks
and 28 weeks for Cis+5-FU and cisplatin
only groups, respectively. Seven treatment
related deaths (16%) were observed in the
combination therapy group and none in
the 5-FU group.

University of
Texas M.D.
Anderson Cancer
Center58

Paclitaxel
No control

None

Paclitaxel

52

At a median follow-up of 9 months,
32 patients remain alive, with an
actuarial median survival duration
of 13.2 months.

The Eastern
Cooperative
Oncology Group

Docetaxel
No control
group

None

Docetaxel

41

An objective response rate of 17%
(90% confidence interval [CI], 8%
to 30% was observed. The most common
toxicity was grade 4 neutropenia, which

(ECOG)59

occurred in 88% of patients.
Peter Enzinger,

None

CPT-11

Mathew Kulke
et al.60

organs, lymphatic channels in the esophagus are present in
the submucosa, just below the muscularis mucosa.
Therefore, the probability of lymph node metastasis in the
submucosal invasive malignancy is as high as 25%. A T2
lesion has a 50% chance of lymphatic spread. This is the
reason, why all but the most superficial esophageal
malignancies should be considered a systemic disease.37-39
Patients with dysplasia and Stage I disease involving
the mucosa have a cure rate of >80%. However, all other
esophageal cancer patients have a cure rate of <50%. Even
the Stage I disease involving the submucosa have a cure rate
40-50%. Regional lymph node involvement results in cure
rate of <25%.37,38
Treatment of Early Disease
Esophagectomy is the most commonly accepted
standard of care for loco-regional disease. Whether a
transthoracic approach is undertaken, or a transhiatal
esophagectomy is performed, the results are dismal, as the
recurrences are high. The overall cure rate with surgery
alone is 12-25%. Surgical mortality is less than 10% and the
results are the same whether the histology is
adenocarcinoma or squamous cell carcinoma. 40-42 The
Japanese Oncology Group performed three randomized
trials in the adjuvant setting. No benefit was seen when
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38

Objective response rate was 15% (95% CI, 2 to 27%).
CPT-11 has activity in advance 1 and gastric
adenocarcinoma although toxicity
must be monitored closely in this
patient population

radiation therapy was compared with Cisplatin/Vindescine
chemotherapy. Again, in the second trial, no benefit was
seen when surgery alone was compared with postoperative
Cisplatin/Vindescine in node positive patients. In the third
study, surgery alone was compared with postoperative
Cisplatin/5FU for 2 cycles; there was trend toward
improvement in disease free survival in patients with node
positive disease. 43-45 This suggests that adjuvant
chemotherapy might be useful in node positive patients,
however 2 cycles may not be enough. Two studies defining
the role of the adjuvant radiation therapy showed no benefit
in improving survival.46,47
Preoperative chemoradiotherapy in improving the
cure rate has been studied. Unfortunately the data is not
very impressive. There are four randomized studies
comparing preoperative chemoradiotherapy followed by
surgery vs. surgery alone.48-51 Three of the four studies are
underpowered. Only one study is positive in patients with
adenocarcinoma of the esophagus; however the controls
with surgery alone had a poor survival of 6% only.51
Another criticism that this study had was that CT scan was
not mandated for staging. The randomized multimodality
therapy on squamous cell carcinoma was negative.50
However, their use of chemotherapy was sub optimal. What
is required is a large randomized, multicenter study testing
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preoperative chemoradiotherapy with surgery alone. Such a
study was initialed by the Intergroup, but was closed
because of poor accrual. The reason is physician-bias;
despite lack of concrete evidence over 50% of the
oncologists in the USA will treat the limited disease with
chemoradiotherapy followed by surgery.52
Two large randomized trials in preoperative
chemotherapy setting deserve attention. Both these studies
compared surgery with preoperative chemotherapy with
5FU/Cisplatin followed by surgery. The RTOG study
showed no improvement with addition of chemotherapy. 53
The MRC study, which is almost twice as large, is showing
a four-year projected survival favoring chemotherapy arm.
However, the follow-up so far is short, staging CT scan was
optional, and the surgical procedure was not standardized . 54
Many randomized trials testing preoperative radiation
therapy did not show benefit with addition of radiation
therapy to surgery.
Those patients with localized disease who are poor
candidates for surgery should be treated with combined
chemoradiotherapy, which is superior to radiotherapy alone.
Five-year survival in one pivotal study was 26% with
chemoradiotherapy vs. 0% with radiotherapy alone. 55

Conclusion
Esophageal Cancer is a challenge to treat for
oncologists. Firstly, over 50% of these patients present as
advanced disease, and hence are incurable. Secondly, early
disease, despite definitive treatment, tends to recur. This is
largely due to unfavorable biology and anatomical
constraints. The most widely used standard of treatment for
early disease is surgical resection. Larger trials are required
to answer the role of addition chemotherapy and radiation
therapy to surgery in localized disease. Newer
chemotherapy and targeted therapy including the antiepidermal growth factor receptors will continue to impact
and define the optimum treatment of this very lethal
malignancy.
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